TruScreen offers an alternative approach to cervical screening, resolving manty of the ongoing issues with conventional screening methods including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructure.

As TruScreen’s results come from an objective, self-checking, AI-enabled system, they are free from the highly subjective human judgement that conventional screening methods are so reliant on.  The TruScreen device has been clinically validated, with large clinical studies including over 40,000 women in multiple settings.*

TruScreen can be effectively used with minimal training to allow for cervical cancer screening without the infrastructure and resource costs associated with conventional, cytology based screening.

As a vast majority of clinical evaluations and trials are conducted in our key markets, there is a large volume of papers that are only available in the native language of the publication’s region.

Below are some English published papers on TruScreen that are available in the public domain.